You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Primary Central Nervous System Lymphomas

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Micro and Macroscopic Level of Primary Central Nervous System

Active, not recruiting
  • Primary Central Nervous System Lymphoma (PCNSL)
  • Tumor samples and MRI
  • Paris, France
    Groupe Hospitalier La Pitié Salpêtrière
Feb 17, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • +3 more
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022

TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System

Completed
  • Lymphoma, B-Cell
    • Montpellier, France
      Uh Montpellier
    Nov 12, 2021

    Lymphoma, B-Cell Trial in Taipei (non-intervention)

    Recruiting
    • Lymphoma, B-Cell
    • non-intervention
    • Taipei, Taiwan
      National Taiwan University Hospital
    Jun 14, 2021

    CNS Lymphoma Trial in Chapel Hill, Winston-Salem (Acalabrutinib, Isavuconazole)

    Recruiting
    • Central Nervous System Lymphoma
    • Chapel Hill, North Carolina
    • +1 more
    Mar 24, 2022

    CNS Lymphoma, Secondary CNS Lymphoma Trial run by the National Cancer Institute (NCI) (TEDD-R, TEDDI-R, Ibrutinib)

    Recruiting
    • Central Nervous System Lymphoma
    • Secondary Central Nervous System Lymphoma
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 23, 2023

    Primary CNS Lymphoma Trial in Paris (PET-MRI)

    Not yet recruiting
    • Primary Central Nervous System Lymphoma
    • Paris, France
      Hôpital Pitié Salpêtrière
    May 20, 2022

    Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

    Recruiting
    • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
    • thiotepa combined with pomalidomide
    • Nanjing, Jiangsu, China
      Jiangsu Province People's Hospital.
    Jun 27, 2023

    Advanced Solid Tumors Harboring NTRK Fusion, Primary CNS Tumors Harboring NTRK Fusion Trial in Guangzhou (ICP-723)

    Recruiting
    • Advanced Solid Tumors Harboring NTRK Fusion
    • Primary Central Nervous System Tumors Harboring NTRK Fusion
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Feb 16, 2023

    Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma Trial (intensity-modulated radiotherapy (IMRT))

    Not yet recruiting
    • Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
    • intensity-modulated radiotherapy (IMRT)
    • (no location specified)
    Jun 4, 2023

    Primary CNS Lymphoma Trial in Hangzhou (Rituximab, Lenalidomide, Methotrexate)

    Completed
    • Primary Central Nervous System Lymphoma
    • Hangzhou, Zhejiang, China
      2nd Affiliated Hospital, School of Medicine, Zhejiang University
    Nov 18, 2022

    Primary CNS Lymphoma Trial in Hanzhou (Orelabrutinib, Rituximab, Methotrexate)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Hanzhou, Zhejiang, China
      2nd Affiliated Hospital, School of Medicine, Zhejiang University
    Nov 3, 2022

    Refractory CNS Lymphoma, Relapsed Primary CNS Lymphoma, Primary CNS Lymphoma Trial in Hangzhou (Nivolumab)

    Active, not recruiting
    • Refractory Central Nervous System Lymphoma
    • +2 more
    • Hangzhou, Zhejiang, China
      Jianmin Zhang
    Jul 3, 2022

    Seen on Brain Imaging in Pediatric Patients Following Proton

    Recruiting
    • Malignant Central Nervous System Neoplasm
    • Malignant Skull Base Neoplasm
    • Medical Chart Review
    • Scottsdale, Arizona
      Mayo Clinic in Arizona
    Jan 6, 2023

    Non-hodgkin Lymphoma Trial (Methotrexate, Rituximab (where available), Ibrutinib)

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • (no location specified)
    Aug 11, 2023

    Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Beijing (GNC-038)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Secondary Central Nervous System Lymphoma
    • Beijing, Beijing, China
      Beijing Tiantan Hospital, Capital Medical University
    Jul 31, 2022

    Primary CNS Lymphoma Trial in Beijing (Orelabrutinib,Rituximab and Methotrexate)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Orelabrutinib,Rituximab and Methotrexate
    • Beijing, Beijing, China
      Hospital 307
    Sep 19, 2022

    Primary CNS Lymphoma Trial in Paris (Glucarpidase, Methotrexate (MTX))

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Paris, France
      Hôpital Pitié-Salpêtrière
    Oct 24, 2022

    Patterns and Clinical Outcomes in Central Nervous System

    Completed
    • Central Nervous System Tuberculosis
      • Wuhan, Hubei, China
      • +1 more
      Aug 25, 2023

      Somatic Mosaicism in Twins Discordant for Childhood Cancer

      Not yet recruiting
      • Pediatric Central Nervous System Tumor
      • +3 more
      • Biospecimen collection
      • Questionnaire Administration
      • (no location specified)
      Sep 19, 2023

      Longitudinal Study for Central Nervous System Vasculitis

      Not yet recruiting
      • Central Nervous System Vasculitis
      • +3 more
        • Cleveland, Ohio
        • +1 more
        Feb 8, 2023

        Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib)

        Recruiting
        • Primary Central Nervous System Lymphoma
        • Shanghai, Shanghai, China
          Ruijin Hospital
        Apr 18, 2022

        Clinical, Radiological, Histologic and Molecular Features

        Recruiting
        • Meningeal Melanocytoma
        • +3 more
          • Nancy, France
            Nancy University Hospital Center
          Jul 31, 2023

          CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma

          Active, not recruiting
          • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
          • DISEASE
          • (no location specified)
          May 4, 2023

          Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial

          Suspended
          • Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
          • Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
          • Bethesda, Maryland
            National Institutes of Health Clinical Center
          Jul 6, 2022